ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2012 > ECCLU - What's New in Haemato-Oncology?
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page


On behalf of ESO and of the Scientific Committee, I have the pleasure of  inviting you to attend the Educational Cancer Convention Lugano.
Thanks to the success of the 2010 edition, the 2012 Convention will be devoted again to haemato-oncology with a programme developed in co-operation with the International Conference on Malignant Lymphoma and the International Extranodal Lymphoma Study Group.

The synergy between these entities has been devised to provide an overview of the latest developments in the field  maintaining a high educational profile.

In particular, the internationally renowned faculty will offer:

- Keynote lectures dealing with relevant biological and clinical aspects of leukaemias  and lymphomas;
- Sessions addressing malignant lymphomas in general, myeloproliferative disorders  and chronic and acute leukaemias;
- Ample time and emphasis will be given to clinical cases presented both by the faculty and the participants who are encouraged to submit abstracts;
- Enhanced interactivity during poster discussion sessions.

I look forward to welcome you to ECCLU 2012 and to your active participation.

Franco Cavalli


F. Cavalli, Chair, Oncology Institute of Southern Switzerland, Bellinzona, CH

B. Coiffier, Centre Hospitalier Lyon Sud, Pierre Bénite, FR
A. Costa, European School of Oncology, Director, Bellinzona, CH and Milano, IT
M.F. Fey, University Hospital, Berne, CH
D. Hölzer, University of Frankfurt, Frankfurt, DE
T.A. Lister, St. Bartholomew's Hospital, London, UK
B. Lowenberg, Erasmus University Medical Centre, Rotterdam, NL
Ch. Renner, University Hospital, Zurich, CH
S. Stilgenbauer, University of Ulm, Ulm, DE
U. Vitolo, Ospedale Maggiore S. Giovanni Battista, Torino, IT
E. Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH

General information


European School of Oncology 
ESO Bellinzona Office
Ospedale Regionale
6500 Bellinzona, Switzerland
Tel:  +41 91 811 8450
Fax: +41 91 811 8051

Programme, abstracts and organisation
Dolores Knupfer - ESO Bellinzona (dknupfer@eso.net)
Laura Richetti - ESO Bellinzona (lrichetti@eso.net)


By 3 February 2012      Abstract submission
By 29 February 2012    Early registration
By 31 March 2012         Late registration


The organisers bear no responsibility for untoward events in relation with the participation in the Convention. Participants are advised to take out their own personal and travel insurance coverage.

The abstract book has been published as a supplement to Critical Reviews in Oncology/Hematology (ONCH Volume 82 Supplement 1, April 2012) contains abstracts of the invited lectures and those submitted by the participants that have been accepted for clinical case discussion, poster presentation or publication only.

Posters will be available for viewing during the whole Convention, whilst the Scientific Committee representatives will visit the posters during lunch time on Saturday 21 April (13:15-14:30) and Sunday 22 April (12:30-13:30) for discussion with the presenters.

Palazzo dei Congressi,
Lugano, Switzerland
Lugano is reachable by plane via Zurich (45-minute flight or 2,5-hour train) or from Milano Malpensa airport (2-hour drive, shuttle service).

How to reach Lugano:
AirplaneLugano-Agno Airport (LUG) is located at 6 km from the town and it is the ideal point of arrival. A shuttle service to/from the centre and hotels is available. Please visit http://www.shuttle-bus.com/ for further information.
TrainFast and easy connections by train are available to Zurich (3 hours) or to Milan Central Station (not airport!).

Milano Malpensa

The transfer from the Milano Malpensa airport to Lugano takes approximately 1 hour and 15 minutes. Please note that booking is required. More information on schedule, duration, cost and booking form for the transfer are available at http://www.malpensaexpress.ch

All participants will be issued a certificate of attendance at the close of the Convention on Sunday, 22 April at 15:15 in return of the completed Evaluation Form.

ECCLU has been appraised and approved by the Accreditation Council of Oncology in Europe (ACOE) acknowledging the quality of the scientific programme and its educational value.
ACOE is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The “Educational Cancer Convention Lugano – ECCLU: What’s new in haemato-oncology?” is designated for a maximum of 11 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, the participant should contact the AMA.
The programme is furthermore accredited with 10 ESMO-MORA category 1 points.

ESO is grateful to the City of Lugano for their interest and continuous support in the organisation of ECCLU, to ESMO for their co-operation and support of travel grants.
ESO is furthermore grateful to the International Conference on Malignant Lymphoma and to the International Extranodal Lymphoma Study Group for their commitment and devotion in defining the high-level programme.

ECCLU is part of the Sharing Progress in Cancer Care programme whose sustaining members are:
Platinum members: Amgen and Eisai
Gold members: Eli Lilly, GlaxoSmithKline Oncology, Merck Serono and Roche
Silver member: Celgene Corporation, Genomic Health, Novartis Oncology and Sanofi Oncology

A limited number of travel grants are assigned on a competitive basis from among participants from middle-low income countries who have had an abstract accepted for oral or for poster presentation.
The curriculum vitae should be submitted at the same time as the abstract (deadline: 27 January) indicating the amount requested to cover economy fare. Successful applicants will be granted registration, accommodation for 2 nights and refund of actual travel costs (flight only) at the end of the Convention.

The official language of the Convention will be English. No translation will be provided.


Faculty list

S. Barrington, St Thomas' Hospital, London, UK
M. Boccadoro, University of Torino, Torino, IT
F. Cavalli, Oncology Institute of Southern Switzerland, Bellinzona, CH
A. Costa, European School of Oncology, Director, Bellinzona, CH and Milano, IT
A. Davies, General Hospital, Southampton, UK
R. Delarue, Necker Hospital, Paris, FR
M.G. Della Porta, Policlinico San Matteo, University of Pavia, Pavia, IT
T. Facon, Lille University Hospital, Lille, FR
M. Federico, University of Modena, Modena, IT
A.J.M. Ferreri, San Raffaele Scientific Institute, Milan, IT
P. Gaulard, Henri Mondor Hospital, Créteil, FR
M. Gospodarowicz, Princess Margaret Hospital, University of Toronto, Toronto, CA
C. Harrison, Guy's Hospital, London, UK
L. Lokey, Prime Oncology, Senior Medical Director, Atlanta, US
T.A. Lister, St. Bartholomew's Hospital, London, UK
M.V. Mateos, University Hospital Salamanca, Salamanca, ES
J. Passweg, University Hospital, Basel, CH
Ch. Renner, University Hospital, Zurich, CH
A. Stathis, Oncology Institute of Southern Switzerland, Bellinzona, CH
S. Stilgenbauer, University of Ulm, Ulm, DE
G. Stüssi, Oncology Institute of Southern Switzerland, Bellinzona, CH
E. Zucca, Oncology Institute of Southern Switzerland, Bellinzona, CH

R.A Malek, Cairo University, Department of Clinical Oncology, Cairo, EG
M. Ali, National Oncology Centre, Department of Clinical Oncology, Sanaa, YE
M. El Sawy, National Cancer Institute of Egypt, Dept. of Medical Oncology and Hematology, Giza, EG
K. Filonenko, National Cancer Institute, Department of Oncohematology, Kyiv, UA
I. Kriachok, National Cancer Institute, Department of Oncohematology, Kyiv, UA
A. Martynchyk, National Cancer Institute, Department of Oncohematology, Kyiv, UA
C. Moreira, Instituto Português de Oncologia do Porto, Onco-Hematology Department, Porto, PT
S. Sretenovic, Clinical Centre Kragujevac, Internal Clinic Centre of Haematology, Kragujevac, RS
N.R. Tumian, Universiti Kebangsaan Malaysia, Medical Center, Cheras, MY
C. Viveiros, Centro Hospitalar Lisboa Norte, Hospital Santa Maria, EPE Hematology Dept., Lisbon, PT

R. Abdeltawab
, Cairo Oncology Center, Department of Hemato-Oncology, Giza, EG
S. Al Jaouni, King Abdul-Aziz University Hospital, Faculty Of Medicine, Hematology Department, Jeddah, SA
S. Banerjee, Medical College Hospital, Department of Medical Oncology, Kolkata, IN
M. Behera, All India Institute Of Medical Sciences (AIIMS), Clinical Oncology, New Delhi, IN
D. Dukovski, University Clinic of Haematology, Haematology Department, Skopje, MK
A. Escriva Vicedo, Dr. Peset University Hospital, Department of Hematology and Hemotherapy, Valencia, ES
A. Fouad, National Cancer Institute, Cairo University, Medical Oncology Department, Cairo, EG
J. Jimenez, National Oncology Institute, Immunohistochemistry Section, Havana City, CU
T. Lofaro, Guy's and St. Thomas', NHS Foundation Trust, Haematology Department, London, UK
C. Moreira, Instituto Português De Oncologia Do Porto, Onco-Hematology Department, Porto, PT
G. Narayanan, Regional Cancer Centre, Dept. of Medical Oncology, Trivandrum, IN
O. Novosad, National Cancer Institute, Oncohaemoblastosis Department, Kiev, UA
J. Ros, Doctor Peset Hospital, Hematology, Valencia, ES
A. Surendran, Regional Cancer Centre, Medical Oncology, Kerala, IN
A. Tolosa, Dr. Peset Hospital, Hematology Department, Valencia, ES
S. Trajkova, University Clinic Of Haematology, Haematology Department, Skopje, MK



21 April


Welcome and opening
F. Cavalli, CH - A. Costa, CH and IT


Chairs: J. Passweg, CH - S. Stilgenbauer, DE   9:15 
Molecular biology (abstract IN1)          G. Stüssi, CH 9:45 Acute leukaemias (abstract IN2)          G. Stüssi, CH
Chronic lymphocytic leukaemia (abstract IN3)         S. Stilgenbauer, DE  


Coffee break


Leukaemias (cont.)
Chairs: J. Passweg, CH - S. Stilgenbauer, DE
Chronic myeloid leukaemia (abstract IN4)         J. Passweg, CH
Myelodysplastic syndrome (abstract IN5)          M.G. Della Porta, IT


Clinical case discussion: Leukaemias
Chairs: J. Passweg, CH - S. Stilgenbauer, DE
Oral presentations of clinical cases based on abstracts submitted by participants
12:15 T-ALL: CNS secondary involvement or meningoencephalitis?
         (abstract OR18)         C. Moreira, PT
12:25 Lenalidomide: a valid therapeutic option in Primary Myelofibrosis (PMF)
(abstract OR19)         C. Viveiros, PT
12:35 Lenalidomide in 5q- syndrome? An efficient therapeutic option
         (abstract OR20 )         C. Viveiros, PT
12:45 Hodgkin's lymphoma transforming into T-cell acute lymphoblastic            leukemia    
         (abstract OR21)         R.A. Malek, EG
12:55 Hemophagocytic lymphohistiocytosis in transplanted Hodgkin lymphoma
         (abstract OR29)         M. El Sawy, EG
13:05 Eosinophilic granuloma? A rare case
         (abstract OR30)         C. Viveiros, PT


Poster session and Lunch


Lymphomas (part I)
Chairs: S. Barrington, UK - T.A. Lister, UK - E. Zucca, IT
14:30 Hodgkin's lymphomas (abstract IN6)        M. Federico, IT 
Role of PET: Staging, re-staging and open questions (abstract IN7)        S. Barrington, UK 
Role of radiotherapy (abstract IN8)         M. Gospodarowicz, CA


Coffee break


Lymphomas (part I - cont.)
Chairs: T.A. Lister UK - E. Zucca, IT 
T-cell lymphomas (abstract IN9)         P. Gaulard, FR
Primary mediastinal lymphoma (abstract IN10)         A. Davies, UK


Clinical case discussion: Lymphomas  
Chairs: T.A. Lister, UK - E. Zucca, IT 
Oral presentations of clinical cases based on abstracts submitted by participants
17:20 Treatment of brain lymphoma by a patient with unfit general condition
         (abstract OR31)         M. Ali, YE
17:30 Procarbazine’s role in symptom control of DLBCL with SNC involvement, a            case report
         (abstract OR32)         C. Moreira, PT
17:40 Secondary pancreatic involvement by diffuse large B-cell lymphoma            presenting as acute pancreatitis
         (abstract OR33)         A. Martynchyk, UA
17:50 Double-hit Non Hodgkin lymphoma-therapeutic problem
         (abstract OR34)         S. Sretenovic, RS

 18:00Novartis sponsored lecture: 
Current treatment landscape in myelofibrosis (abstract IN11) 
C. Harrison, UK
 18:30Welcome cocktail 


22 April


Lymphomas (part II) 
Chairs: F. Cavalli, CH - Ch. Renner, CH 8:00 
Marginal-zone lymphomas (abstract IN12)           E. Zucca, CH  8:30 Follicular lymphomas (abstract IN13)           T.A. Lister, UK 9:00 DLBCL (abstract IN14)           Ch. Renner, CH  9:30 Primary  CNS lymphoma (abstract IN15)          A.J.M. Ferreri, IT 
New drugs (abstract IN16)          A. Stathis, CH

 10:30  Coffee break


Practical considerations in the management of multiple myeloma
An educational activity organized by Prime Oncology 

11:00 Welcome, introduction, and demographic              questions                                     L. Lokey, US        Case #1 - Newly diagnosed myeloma: Optimizing outcomes for            the transplant eligible patient
         T. Facon, FR
11:25 Q & A                                              
11:30 Case #2 - Relapsed myeloma: Systematically evaluating our             options
         M.V. Mateos, ES
11:55 Q & A
12:00 Case #3 - Myeloma in the elderly: How “gentle” can we be? 
         M. Boccadoro, IT 
12:30 Concluding remarks 
         L. Lokey, US


Poster session and Lunch


Amgen sponsored lecture: 
LNH03-6B GELA study with darbepoetin alfa 
R. Delarue, FR 


Clinical case discussion: Myeloma  
Chair: Ch. Renner, CH 
Oral presentations of clinical cases based on abstracts submitted by participants
14:00 Cutaneous plasmacytomas in a patient with refractory            nonsecretory myeloma 
         (abstract OR54)         C. Moreira, PT
14:10 Non secretory multiple myeloma presenting with extensive            extramedullary plasmacytoma
         (abstract OR55)         N.R. Tumian, MY 
14:20 The differential diagnosis: multiple myeloma or Waldenström's             macroglobulinemia?
         (abstract OR56)         I. Kriachok, UA
14:30 Coincident of multiple myeloma and non-hodgkin’s lymphoma in female
         (abstract OR57)         K. Filonenko, UA 
 14:45Closing remarks and adjournment 
F. Cavalli, CH

PO22 Honey reduces chemoradiotherapy-induced mucositis in pediatric cancer patients
PO23 Health and quality of life outcomes in patient with sickle cells disease
PO24 The prevalence of the most common causes for primary thrombophilia among Saudi patients attending the anticoagulant clinic
PO25 Clinico-pathologic factors affecting short term mortality in paediatric and adolescent ALL patients
PO27 Hematologic and cytogenetic response to Imatinib mesylate in chronic myeloid leukemia
PO35 Total skin electron beam radiation therapy in cutaneous T-cell lymphoma- a retrospective experience
PO36 B-cell non-Hodgkin lymphoma of small lymphocytes
PO37 Rituximab maintenance therapy in diffuse large B-cell lymphoma
PO38 Re-treatment versus rituximab maintenance therapy at progression in patients   with follicular lymphoma
PO39 Long-term survival after histologic transformation from high grade B cell non-Hodgkin's lymphoma to low grade follicular lymphoma and Hodgkin's disease in the same patient
PO40 Bacterial contamination of platelets for transfusion in transplanted lymphoma patients
PO41 Rapidly progressive transformed follicular lymphoma, a case report
PO42 Non-Hodgkin's lymphoma of bone
PO43 Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia
PO44 Primary bone marrow diffuse large B cell lymphoma: a case report
PO45 A case of primary cardiac lymphoma with systemic involvement
PO46 Sustained remission after mTOR inhibitor in a case of refractory HD
PO47 The introduction of immunohistochemistry for the diagnosis of lymphomas at the Pathology Department of the National Institute of Oncology, Cuba




3 FEBRUARY 2012).

Participants are invited to submit an abstract on basic research, clinical study or a clinical case in heamato-oncology, in one of the following categories:

• Leukaemias
• Lymphomas
• Myeloma

Abstracts on basic research or clinical studies will be considered for poster presentation only.
Abstracts on clinical cases will be considered for oral presentation or poster presentation.

Participants submitting abstracts on a clinical case are encouraged to describe frequent disorders, where a clinical-therapeutic decision making is controversial.
The oral presentation of clinical cases will be scheduled with a 5-minute presentation (maximum of 5 slides) followed by a 5-minute discussion.

Accepted abstracts will be published in the ECCLU 2012 Abstract Book, supplement to Critical Reviews in Oncology/Hematology.


• The abstract should be limited to 2000 characters, including the title
• The title should  be in lower case letters
• Each author should be listed with First Name, followed by Family Name
• The first author should be underlined (first author = corresponding author and presenter)
• List affiliations after the authors’ list
• The full address with e-mail address, phone and fax numbers of the first author (+ corresponding author and presenter) must be provided. The first author will receive an acknowledgement of receipt and all subsequent communication by e-mail.
• For abstracts accepted for presentation, the first author will be the presenting author and is requested to register and participate in the Convention.
• It is the responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made.

The acknowledgement of receipt of the abstract will immediately follow the submission. The outcome will be notified by 13 February to the first author who will be required to register to the Convention (early registration deadline: 29 February).